Oct. 30, 2024 For release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 374-1878 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products • Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue fro ...